Risk Management Only Part Of Behind-The-Counter Orders – Von Eschenbach
Executive Summary
Enactment of legislation to strengthen FDA's post-marketing authority is not the only hurdle to clear before the agency could begin requiring "behind-the-counter" sales of certain nonprescription drugs, Commissioner Andrew von Eschenbach says
You may also be interested in...
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
The Third Way? Von Eschenbach Promotes Behind-The-Counter Drug Class
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew von Eschenbach told the Consumer Healthcare Product Association's annual executive conference
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.